Key Points
- Ultragenyx director Shehnaaz Suliman sold 5,740 shares on May 18 at an average price of $25.12, worth about $144,189. After the sale, Suliman still held 27,951 shares, a 17.04% reduction in the position.
- The stock fell 3.2% and opened Tuesday at $24.19, with the company valued at about $2.38 billion. The shares are trading below the 200-day moving average of $26.38.
- Recent earnings missed expectations, as Ultragenyx reported a loss of $1.84 per share versus estimates of a $1.49 loss and revenue of $136 million versus $158.19 million expected. Analysts still view the stock as a Moderate Buy on average, with a consensus target price of $60.41.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) Director Shehnaaz Suliman sold 5,740 shares of the company's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $25.12, for a total value of $144,188.80. Following the completion of the transaction, the director directly owned 27,951 shares in the company, valued at $702,129.12. This trade represents a 17.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Ultragenyx Pharmaceutical Stock Down 3.2%
Shares of Ultragenyx Pharmaceutical stock opened at $24.19 on Tuesday. The stock's fifty day moving average is $23.14 and its two-hundred day moving average is $26.38. The company has a market capitalization of $2.38 billion, a PE ratio of -3.96 and a beta of 0.39. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $42.37.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The business had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business's revenue was down 2.2% compared to the same quarter last year. During the same period last year, the company earned ($1.57) EPS. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.63 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on the company. Weiss Ratings upgraded Ultragenyx Pharmaceutical from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 8th. JPMorgan Chase & Co. lowered their target price on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an "overweight" rating for the company in a report on Thursday, March 12th. Guggenheim lowered their target price on Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a "buy" rating for the company in a report on Friday, May 8th. HC Wainwright lowered their target price on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, February 17th. Finally, Canaccord Genuity Group lowered their target price on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a "buy" rating for the company in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $60.41.
Get Our Latest Stock Report on RARE
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Assetmark Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 1,024 shares during the last quarter. Huntington National Bank raised its stake in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 393 shares during the last quarter. Danske Bank A S purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth about $39,000. Parallel Advisors LLC raised its stake in shares of Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,440 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 1,169 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.
About Ultragenyx Pharmaceutical
(
Get Free Report)
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
